... withAttention -Deficit/ HyperactivityDisorderin theUnited Kingdom. Value Health 2008, 11(3):376-388.28. Brown TE: Emerging Understanding of Attention- Deficit Disorders andComorbidities in Attention- Deficit Disorders ... Modi N, Linde-mulder E, Wigal S: Development of a new once-a-day formula-tion of methylphenidate for the treatment of attention- deficit/ hyperactivity disorder: proof -of- concept and proof -of- product ... ato-moxetine and MPH on the grounds ofclinical efficacy in terms of standard measures of ADHD symptom control[21] though there has been increasing evidence in favour of MPH [22]. However, atomoxetine...
... mara.hutz@ufrgs.brADHD, attention- deficit/ hyperactivity disorder; BAIAP2, brain-specific angiogenesis inhibitor 1-associated protein 2 gene; BDKRB2, brady-kinin receptor B2 gene; DAT1, dopamine transporter ... the signal transduction path-ways of insulin and insulin-like growth factors. This protein is highly expressed in the left cortex and seems to be involved in neuronal proliferation, survival ... basis of hypotheses that catecholaminergic pathways in the brain are responsible for ADHD. However, many negative association findings have been reported, indicating a limited success for investigations...
... struggled significantly with learning Clinical use of a modified release methylphenidate in the treatment of childhood attentiondeficithyperactivitydisorder Inyang Takon* QE II Hospital, ... 19. Findling RL, Quinn D, Hatch SJ, Cameron SJ, DeCory HH, McDowell M: Comparison of the clinical efficacy of twice-daily Ritalin and once-daily Equasym XL with placebo in children with attention ... versions will be made available soon. Clinical use of a modified release methylphenidate in the treatment of childhood attention deficithyperactivity disorder Annals of General Psychiatry 2011, 10:25...
... trouble concentrating in class22 has difficulty waiting in lines or awaiting turn in games or group situations23 Leaves seat in classroom or other situation in which remaining seated is expected24 ... of more time spent on video games may also place these individuals at increased riskfor problems in school.BackgroundThe introduction of the telegraph in the nineteenth cen-tury ushered in ... than one hour of time playingvideo games. It would be interesting to examine the lattercohort in more detail to determine if there is a linear rela-tionship between time spent playing video games...
... 2(CPTimpulsivity)Factor 3 (Clinical hyperactivity) Factor 4 (Clinical inattention)SNAP-IVInattention 0.08 0.07 0.36 0.79 Hyperactivity 0.09 0.08 0.85 0.29ADHD-RSInattention 0.19 0.11 -0.06 0.89 Hyperactivity ... todeter mine: First, whether there are sustainable improve-ments in ADHD clinical symptoms and neurocognitivefunction in realistic clinical settings. Second, whetherthe differences in ADHD clinical ... and combined t ype, according to the predomi-nant clinical manifestations of inattention, hyperactivity, and impulsivity. The validity of DSM-IV ADHD predo-minantly inattentive and combined types...
... Treatment of Attention- Deficit/ Hyperactivity Disorder. Biol Psychiatry 2011, 69(12):e145-57.3. American Association of Pediatrics: Clinical practice guideline: diagnosisand evaluation of the ... CJ,Conners CK, Potter WZ: Results from 2 proof -of- concept, placebo-controlled studies of atomoxetine in children with attention- deficit/ hyperactivity disorder. J Clin Psychiatry 2002, 63(12):1140-1147.22. ... 11:176http://www.biomedcentral.com/1471-244X/11/176Page 4 of 8 RESEARCH ARTICLE Open AccessComparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attentiondeficithyperactivitydisorder in children and...
... portion of a clini-cal trial design. In a study optimizing the treatment of ADHD in 25 adults, the combination of atomoxetine andmethylphenidate resulted in small statistically significantmean increases ... overall16% rate of discontinuation due to AEs.The safety and tolerability findings from this study mirrorprevious findings of cardiovascular effects in patients whohave received combined treatment ... placebo having a mean increase in weight of 0.84 kg compared with patients in the ATX/MPH groupwho had a mean decrease in weight of 0.89 kg (P ≤ .05).The mean atomoxetine dose at endpoint was...
... study endpoint. Improvement in compliance mayreflect increasing capacity to establish a routine of patchadministration with time, although noncompliance isoften underestimated in any clinical ... Psychiatr Clin North Am1992, 15:191-222.20. Robison LM, Sclar DA, Skaer TL, Galin RS: National trends in theprevalence of attention- deficit/ hyperactivitydisorder andthe prescribing of methylphenidate ... hours of tutoring, nursing, homehealthcare, or other services increased from 60.2% atbaseline to 77.6% at endpoint. Furthermore, from base-line to endpoint, the percentage of caregivers reporting...
... 123–9. THE HISTORY OFATTENTIONDEFICITHYPERACTIVITYDISORDER 9Coinciding with the work of Douglas, researchers in Northern Europe became more interested in the concept ofhyperactivity as a ... understanding of the diagnosis and classifi cation of ADHD in childhood. In addition, we will describe the rating scales used in aiding diagnosis. We begin by tracing the evolution of our understanding ... criteria for Hyperkinetic Disorder used in the current edition of the International Classifi cation of Diseases (ICD-10) in that specifi c behaviour symptoms of inattention and hyperactivity- impulsivity...
... except of onestudy which included a combined sample of children 6–18 years of age referred for psychiatric services who werediagnosed with a variety of disorders within a spectrum of attention- deficit ... purposes)tive of children in large pediatric populations has severaldistinct benefits beyond the clinical setting. It can aid in identifying subgroups of children who are at-risk forhealth problems, in ... Measuring quality of life in chil-dren with attention- deficit/ hyperactivitydisorder and theirfamilies: Development and evaluation of a new tool. Archives of Pediatric and Adolescent Medicine...
... efficacy in helping smokers with attentiondeficithyperactivitydisorder (ADHD) to stopsmoking.Methods: To investigate potential efficacy for relieving nicotine withdrawal symptoms and promoting ... 4 of 6 smoking in adult non-ADHD smokers who were nottrying to stop smoking [5,6]. To date, the only large trial of methylphenidate in smokers has been in smokerswith AttentionDeficitHyperactivity ... of dopamine by binding tothe dopamine transporter in the presynaptic cell mem-brane and increase extracellular dopamine levels [2,3].Similarities in neuropsychologic effects between nicotineand...
... Delineating Auditory Processing Disorder (APD)and AttentionDeficitHyperactivityDisorder (ADHD): A Conceptual,Theoretical, and Practical Framework. In An introduction to auditoryprocessing ... pre-vious findings, as no other studies have investigatedbrain activation during antisaccades in children withADHD. However, it should be noted that there areinconsistent findings in imaging studies ... movements in attention- deficit hyperactivity disorder. J Neurophysiol 2003, 90(1):503-514.9. Mostofsky SH, Lasker AG, Cutting LE, Denckla MB, Zee DS: Oculomotorabnormalities inattentiondeficit hyperactivity...
... absence of any further increase in treatment inten-sity, a disappointing clinical profile and subsequent lowadoption rate of lisdexamphetamine, and denial of mar-ket access for modafinil and ... potential clinical uses and mechanisms of action. Journal ofClinical Psychi-atry 2006, 67(4):554-566.56. Turner D: A review of the use of modafinil for attention- defi-cit hyperactivity disorder. ... CK, Potter WZ: Results from 2 proof -of- concept, pla-cebo-controlled studies of atomoxetine in children with attention- deficit/ hyperactivity disorder. Journal ofClinical Psychi-atry 2002, 63(12):1140-1147.93....